Tyrosine kinase inhibitor independent gene expression signature in CML offers new targets for LSPC eradication therapy
E. Gomez-Castaneda, S. Rogers, C. Munje, J. Bittencourt-Silvestre, M. Copland, D. Vetrie, L. Hopcroft, H. Jorgensen, T. Holyoake
The paper identifies TKI-independent genes in CML LSC that could be targeted for new therapies, showing that gemtuzumab-ozogamicin and cyclosporine A have stronger effects on CML cells than healthy cells.
Cancers · Oct 26, 2022Peer-reviewedCancer Biology